Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial - 29/05/24
, Mathieu Roumiguié, MD b, Ashish M Kamat, ProfMD c, Neal D Shore, MD d, Joost L Boormans, ProfMD PhD e, Ahmet Adil Esen, ProfMD f, Thierry Lebret, ProfMD PhD g, Shuya Kandori, MD h, Dean F Bajorin, ProfMD j, Laurence E M Krieger, MD k, Scot A Niglio, MD l, Edward M Uchio, ProfMD m, Ho Kyung Seo, MD PhD n, Ronald de Wit, ProfMD PhD e, Eric A Singer, ProfMD o, p, Petros Grivas, MD PhD q, Hiroyuki Nishiyama, ProfMD i, Haojie Li, MD r, Pranshu Baranwal, MSc r, Margot Van den Sigtenhorst-Fijlstra, MD PhD s, Ekta Kapadia, MD r, Girish S Kulkarni, ProfMD PhD tSummary |
Background |
The KEYNOTE-057 trial evaluated activity and safety of pembrolizumab in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. In cohort A (patients with carcinoma in situ, with or without papillary tumours) of the KEYNOTE-057 study, pembrolizumab monotherapy led to a complete response rate of 41% at 3 months, and 46% of responders maintained a response lasting at least 12 months. Here, we evaluate pembrolizumab monotherapy in cohort B of patients with papillary tumours without carcinoma in situ.
Methods |
KEYNOTE-057 is a single-arm, phase 2 study in 54 sites (hospitals and cancer centres) in 14 countries. Cohort B eligible patients were aged 18 years and older, had an Eastern Cooperative Oncology Group performance status of 0–2, and had BCG-unresponsive high-risk non-muscle-invasive bladder cancer with papillary tumours (high-grade Ta or any-grade T1) without carcinoma in situ. Transurethral resection of bladder tumour within 12 weeks of first pembrolizumab dose was required. Patients received pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles. Primary endpoint was 12-month disease-free survival of high-risk non-muscle-invasive bladder cancer or progressive disease as assessed by cystoscopy, cytology, and central pathology and radiology review. Activity was assessed in all patients who received at least one dose of the study drug and had a baseline evaluation. Safety was assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov number, NCT02625961, and is ongoing.
Findings |
Between April 12, 2016, and June 17, 2021, 132 patients (104 [79%] men and 28 [21%] women) who had received a median of ten (IQR 9–15) previous BCG instillations were enrolled into cohort B of the study. Patients received a median of 10 cycles (IQR 6–27) of pembrolizumab. At data cutoff date, Oct 20, 2022, median follow-up was 45·4 months (IQR 36·4–59·3) and five (4%) of 132 patients remained on treatment. The 12-month disease-free survival was 43·5% (95% CI 34·9–51·9). Treatment-related adverse events occurred in 97 (73%) of 132 patients; 19 (14%) had a grade 3 or 4 treatment-related adverse event; the most common grade 3 or 4 treatment-related adverse events were colitis (in three [2%] patients) and diarrhoea (in two [2%]). 17 (13%) of 132 patients experienced serious treatment-related adverse events, of which colitis (three patients [2%]) was most common. No treatment-related deaths occurred.
Interpretation |
Pembrolizumab monotherapy showed antitumour activity and manageable toxicity in patients with BCG-unresponsive high-risk Ta or T1 bladder cancer without carcinoma in situ and could potentially be a suitable treatment option for patients who decline or are ineligible for radical cystectomy. Findings will need to be confirmed in a randomised controlled trial.
Funding |
Merck Sharp & Dohme.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 6
P. 720-730 - juin 2024 Retour au numéro
Article précédent
- Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
- Bob T Li, Funda Meric-Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Anderson, Giuseppe Curigliano, Maria de Miguel, Maitri Kalra, Do-Youn Oh, Joon Oh Park, Sophie Postel-Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura, DESTINY-PanTumor01 study group, Bob T Li, Funda Meric-Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Anderson, Giuseppe Curigliano, Maria de Miguel, Maitri Kalra, Do-Youn Oh, Joon Oh Park, Sophie Postel-Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura
- Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study
- Milena Sant, Claudia Vener, Roberto Lillini, Silvia Rossi, Simone Bonfarnuzzo, Rafael Marcos-Gragera, Marc Maynadié, Kaire Innos, Keiu Paapsi, Otto Visser, Alice Bernasconi, Elena Demuru, Corrado Di Benedetto, Seyed Mohsen Mousavi, Marcel Blum, Philip Went, Diego Serraino, Damien Bennett, Maria-Jose Sánchez, Roberta De Angelis, EUROCARE-6 Working Group, Monika Hackl, Elizabeth Van Eycken, Nancy Van Damme, Zdravka Valerianova, Mario Sekerija, Vasos Scoutellas, Anna Demetriou, Ladislav Dušek, Denisa Krejici, Hans Storm, Margit Mägi, Kaire Innos, Janne Pitkäniemi, Michel Velten, Xavier Troussard, Anne-Marie Bouvier, Valerie Jooste, Anne-Valérie Guizard, Guy Launoy, Sandrine Dabakuyo Yonli, Marc Maynadié, Anne-Sophie Woronoff, Jean-Baptiste Nousbaum, Gaëlle Coureau, Alain Monnereau, Isabelle Baldi, Karima Hammas, Brigitte Tretarre, Marc Colonna, Sandrine Plouvier, Tania D’Almeida, Florence Molinié, Anne Cowppli-Bony, Simona Bara, Adeline Debreuve, Gautier Defossez, Bénédicte Lapôtre-Ledoux, Pascale Grosclaude, Laetitia Daubisse-Marliac, Sabine Luttmann, Andrea Eberle, Roland Stabenow, Alice Nennecke, Joachim Kieschke, Sylke Zeissig, Bernd Holleczek, Alexander Katalinic, Helgi Birgisson, Deirdre Murray, Paul M Walsh, Guido Mazzoleni, Fabio Vittadello, Francesco Cuccaro, Rocco Galasso, Giuseppe Sampietro, Stefano Rosso, Cinzia Gasparotti, Giovanni Maifredi, Margherita Ferrante, Rosalia Ragusa, Antonella Sutera Sardo, Maria Letizia Gambino, Monica Lanzoni, Paola Ballotari, Erica Giacomazzi, Stefano Ferretti, Adele Caldarella, Gianfranco Manneschi, Gemma Gatta, Milena Sant, Paolo Baili, Franco Berrino, Laura Botta, Annalisa Trama, Roberto Lillini, Alice Bernasconi, Simone Bonfarnuzzo, Claudia Vener, Fabio Didonè, Paolo Lasalvia, Lucia Buratti, Giovanna Tagliabue, Diego Serraino, Luigino Dal Maso, Riccardo Capocaccia, Roberta De Angelis, Elena Demuru, Francesco Cerza, Fabrizio Di Mari, Corrado Di Benedetto, Silvia Rossi, Mariano Santaquilani, Serenella Venanzi, Marco Tallon, Luca Boni, Silvia Iacovacci, Valerio Gennaro, Antonio Giampiero Russo, Federico Gervasi, Gianbattista Spagnoli, Luca Cavalieri d’Oro, Mario Fusco, Maria Francesca Vitale, Mario Usala, Walter Mazzucco, Maria Michiara, Giorgio Chiranda, Giuseppe Cascone, Concetta Patrizia Rollo, Lucia Mangone, Fabio Falcini, Rossella Cavallo, Daniela Piras, Anselmo Madeddu, Francesca Bella, Anna Clara Fanetti, Sante Minerba, Giuseppina Candela, Tiziana Scuderi, Roberto Vito Rizzello, Fabrizio Stracci, Massimo Rugge, Angelita Brustolin, Santa Pildava, Giedre Smailyte, Miriam Azzopardi, Tom Børge Johannesen, Joanna Didkowska, Urszula Wojciechowska, Magdalena Bielska-Lasota, Ana Pais, Maria José Bento, Ana Maia Ferreira, António Lourenço, Chakameh Safaei Diba, Vesna Zadnik, Tina Zagar, Carmen Sánchez-Contador Escudero, Paula Franch Sureda, Arantza Lopez de Munain, Marta De-La-Cruz, María Dolores Rojas, Araceli Aleman, Ana Vizcaino, Rafael Marcos-Gragera, Arantza Sanvisens, Maria Josè Sanchez, Maria Dolores Chirlaque Lopez, Antonia Sanchez-Gil, Marcela Guevara, Eva Ardanaz, Jaume Galceran, Maria Carulla, Yvan Bergeron, Christine Bouchardy, Seyed Mohsen Mousavi, Philip Went, Marcel Blum, Andrea Bordoni, Otto Visser, Sarah Stevens, John Broggio, Damien Bennett, Anna Gavin, David Morrison, Dyfed Wyn Huws
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?